Literature DB >> 12790051

Immunobiologic consequences of assist devices.

Silviu Itescu1, Michael Schuster, Elizabeth Burke, Jan Ankersmit, Alfred Kocher, Mario Deng, Ranjit John, Katherine Lietz.   

Abstract

The aberrant state of monocyte and T-cell activation resulting from these host-device interaction is accompanied by two parallel processes: (1) selective loss of Th1 cytokine-producing CD4 T cells through activation-induced cell death, and (2) unopposed activation of Th2 cytokine-producing CD4 T cells resulting in B-cell hyperreactivity and dysregulated immunoglobulin synthesis via Th2 cytokines and heightened CD40 ligand-CD40 interactions. The net result of these events is that on one hand the VAD recipient develops progressive defects in cellular immunity and is at increased risk of serious infection, and on the other hand the VAD recipient is more likely to develop allosensitization, posing a significant risk to successful transplant outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12790051     DOI: 10.1016/s0733-8651(02)00135-2

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  6 in total

1.  False positive hepatitis C antibody test results in left ventricular assist device recipients: increased risk with age and transfusions.

Authors:  Grace Y Minamoto; Doreen Lee; Adriana Colovai; Dana Levy; Ljiljana Vasovic; Keith W Roach; Jonathan Shuter; Daniel Goldstein; David D'Alessandro; Ulrich P Jorde; Victoria A Muggia
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

2.  Evaluation of clinical biomaterial surface effects on T lymphocyte activation.

Authors:  Analiz Rodriguez; James M Anderson
Journal:  J Biomed Mater Res A       Date:  2010-01       Impact factor: 4.396

Review 3.  Management of allosensitized cardiac transplant candidates.

Authors:  Mauricio Velez; Maryl R Johnson
Journal:  Transplant Rev (Orlando)       Date:  2009-10       Impact factor: 3.943

4.  Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products.

Authors:  Myra Coppage; Marc Baker; Lawrence Fialkow; Danielle Meehan; Kelly Gettings; Leway Chen; H Todd Massey; Neil Blumberg
Journal:  Hum Immunol       Date:  2009-03-09       Impact factor: 2.850

Review 5.  Perioperative pharmacotherapy in patients with left ventricular assist devices.

Authors:  Nicholas C Dang; Yoshifumi Naka
Journal:  Drugs Aging       Date:  2004       Impact factor: 4.271

Review 6.  Transplant infectious disease: implications for critical care nurses.

Authors:  Sandra A Cupples
Journal:  Crit Care Nurs Clin North Am       Date:  2011-09       Impact factor: 1.326

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.